Result card

  • EFF7a: Are IVIG effective in improving disease specific health-related quality of life of patients with mild-to- moderate Alzheimer’s disease when compared to placebo or acetyl cholinesterase inhibitors?
  • EFF7b: Are IVIG effective in improving disease specific health-related quality of life of caregivers of patients with mild-to-moderate Alzheimer’s disease when compared to placebo or acetyl cholinesterase inhibitors? Jump to
  • EFF7c: Are IVIG effective in improving disease specific health-related quality of life of caregivers of patients with moderate-to-severe Alzheimer’s disease when compared to placebo or memantine? Jump to
English

Are IVIG effective in improving disease specific health-related quality of life of patients with mild-to- moderate Alzheimer’s disease when compared to placebo or acetyl cholinesterase inhibitors?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

Data on disease specific health related quality of life changes of patients, measured by QOLAD, were available from 284 patients (out of 383) of one RCT {NCT00818662}. See Appendix 2 for details.

Mean score change from baseline at 18 months in QOLAD did not differ between IVIG 400 mg/kg group (99 patients) and placebo group (86 patients) (1.1, 95% CI -0.2 to 2.3; P = 0.094) and between IVIG 200 mg/kg group (99 patients) and placebo group (86 patients) (1.1, 95% CI -0.2 to 2.3; P = 0.094).

Table 5. Summary of findings: Disease specific health related quality of life in patients with mild-to-moderate AD treated with IVIG

Disease specific health related quality of life in patients: QOLAD mean score change from baseline to 18 months

1.1 (95% CI -0.2 to 2.3); P = 0.094

1.1 (95% CI -0.2 to 2.3); P = 0.094

Very low

 

Important
Completely
Vignatelli L et al. Result Card EFF7a In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 24 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

Are IVIG effective in improving disease specific health-related quality of life of caregivers of patients with mild-to-moderate Alzheimer’s disease when compared to placebo or acetyl cholinesterase inhibitors?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

Data on disease specific health related quality of life changes of caregivers, measured by QOLAD, were available from 290 patients (out of 383) of one RCT {NCT00818662}. See Appendix 2 for details.

Mean score change from baseline at 18 months in QOLAD did not differ between IVIG 400 mg/kg group (99 caregivers) and placebo group (92 caregivers) (-1.1 95% CI -2.3 to 0.2; P = 0.096) and between IVIG 200 mg/kg group (99 caregivers) and placebo group (92 caregivers) (-1.0, 95% CI -2.2 to 0.3; P = 0.123).

Table 6. Summary of findings: Disease specific health related quality of life in in caregivers of patients with mild-to-moderate AD treated with IVIG

Disease specific health related quality of life in caregivers: QOLAD mean score change from baseline to 18 months

-1.1 95% CI -2.3 to 0.2; P = 0.096

-1.0, 95% CI -2.2 to 0.3; P = 0.123

Very low

 

Important
Completely
Vignatelli L et al. Result Card EFF7b In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 24 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

Are IVIG effective in improving disease specific health-related quality of life of caregivers of patients with moderate-to-severe Alzheimer’s disease when compared to placebo or memantine?

Authors: Luca Vignatelli, Luciana Ballini, Susanna Maltoni, Jelena Barbaric, Mirjana Huic, Pernilla Östlund.

Internal reviewers: Gerardo Atienza, Agnes Mannik

The same methodology was used as described in section for the whole domain.

No evidence on disease specific health related quality of life is available for caregivers of patients with moderate-to-severe AD.

Important
Completely
Vignatelli L et al. Result Card EFF7c In: Vignatelli L et al. Clinical Effectiveness In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 24 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

References